Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway - BioSpace biospace.com/press-releases…

Pharmather eyes commercialization of Parkinson’s ketamine drug parkinsonsnewstoday.com/news/pharmathe…

It’s not just tremors in Parkinson's, we need to broaden our rehabilitation lens beyond balance and gait. We need rehabilitation strategies for sleep and autonomic symptoms like constipation, urinary and sexual dysfunction. We’ve long focused on movement, but what about the

Wow! Big data dump: Global Neurodegeneration Proteomics Consortium presents 250M protein measurements from >35K biofluid samples (plasma, serum & cerebrospinal fluid) contributed by 23 partners, spanning #Alzheimers, #Parkinsons, frontotemporal dementia & #ALS; Biomarker discovery nature.com/articles/s4159…

Dopamine acts like a laser pointer and not a sprinkler. Dopamine isn’t just about pleasure or motion, it’s about precision coding at the cellular level. Maybe we should stop stereotyping dopamine as a simple splashy brain signal. An interesting new study in Science by Yee, Ford

Can specialized physical therapy help you to live longer with Parkinson’s? What if physical therapy did more than improve balance and reduce falls? A new Dutch study by Ypinga, Bloem and colleagues just dropped and the results are fascinating. Specialized physical therapy, like

What are the FDA approved drugs for non-motor and neuropsychiatric symptoms in Parkinson's? We need to do better and this needs to be part of the plan. pdplan.org Thanks Jen Goldman for updating us on this 'lack of progress.' Let's do better as people are counting on

Unmet needs in the pharmacological management of motor symptoms in Parkinson's disease - Beatrice Heim, Werner Poewe, 2025 journals.sagepub.com/doi/10.1177/18…

Shades of grey: The continuum of therapies for Parkinson's disease along the spectrum of credibility - Araceli Alonso-Canovas, Olaf M Dekkers, Bas Bloem, 2025p journals.sagepub.com/doi/10.1177/18…

Could gene therapy silence Parkinson’s progression? A study in primates just showed it may be possible. Steece-Collier and colleagues knocked it out of the park in their new paper in Molecular Therapy. The group studied aged macaques and demonstrated that targeting CaV1.3

Sumitomo Pharma apply for marketing authorisation of a stem cell replacement therapy for Parkinson's biz.chosun.com/en/en-science/…

Replenishing the brain’s natural stores of lithium can protect against and even reverse Alzheimer’s disease go.nature.com/4mt8jSz

Press summary associated with this research: medicalxpress.com/news/2025-08-r…

The Parkinson's Foundation has launched PD Trial Navigator to help increase enrollment in clinical studies testing gene-targeted therapies. buff.ly/Kvwq6tP

“As such, moderation in the communication of prognosis and of the potential of new medicines is essential, so that PwP can maintain hope rather than being misled by hype.” in ⁦Journal of Parkinson's Disease⁩ journals.sagepub.com/doi/10.1177/18…

Coincidentally in today’s Guardian - theguardian.com/technology/202…

What medicines do people with Parkinson's want? Tiago Outeiro , Carmo Bastos and I try to answer the question in Journal of Parkinson's Disease #Parkinsons . It's #openaccess as well. journals.sagepub.com/doi/full/10.11…

Honored to be asked to contribute to the Parky Charter effort by the wonderful Movers & Shakers Movers & Shakers: a podcast about Parkinson's - the Quest for a Cure (for #Parkinsons) linkedin.com/pulse/parky-ch…

Remember kids: "Pathology does not mean disease. Most individuals with pathology will never have disease" Wonderful letter from Alberto J Espay & Andrew Lees! "In the reality we inhabit, we have made Lewy pathology not just a marker of PD, but its very maker! journals.sagepub.com/doi/10.1177/18…

We’re excited to announce that recruitment for the first multi-arm, multi-stage (MAMS) platform for Parkinson’s in the UK – EJS ACT-PD – is open. This project will continuously test new therapies that could impact Parkinson's progression: buff.ly/W7eqbec #ejsactpd